Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST).

ABSTRACT:

Background

Patients with advanced gastrointestinal stromal tumours (GISTs) resistant to the tyrosine kinase inhibitors imatinib and sunitinib may be treated with regorafenib, which resulted in a median progression-free survival (PFS) of 4.8 months in the GRID trial. Also, pazopanib, another tyrosine kinase inhibitor, has been studied in a randomized, placebo-controlled trial (PAZOGIST) in the third line, which showed a PFS of 45.2% 4 months after study entry, but patients intolerant to sunitinib were also included. We designed another trial evaluating pazopanib, enrolling only patients with progression on both imatinib and sunitinib.

Patients and methods

Since all eligible patients had progressive disease, we preferred a non-randomized, phase II multicentre trial so that all

SUBMITTER: Eriksson M 

PROVIDER: S-EPMC8287147 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature